PARTNERS

Santen

In March 2014, Santen Pharmaceutical Co., Ltd., a global ophthalmology company, licensed from us exclusive worldwide rights to develop and commercialize our endoglin antibodies for ophthalmology indications, including wet AMD. In June 2015, Santen filed an IND with the FDA, for the initiation of clinical studies for DE-122 in patients with wet AMD. DE-122 is the ophthalmic formulation of our proprietary endoglin antibody, TRC105. Santen initiated a Phase 1/2 clinical trial of DE-122 in wet AMD patients in 2015, and this early clinical trial includes testing of DE-122 in patients receiving treatment with a VEGF inhibitor.

Santen

In September 2016, we entered into a strategic licensing collaboration with Janssen Pharmaceutica N.V., for two novel oncology assets from Janssen’s early oncology development portfolio. The agreement grants us the rights to develop TRC253 (formerly JNJ-63576253), a novel small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors which display drug resistance to currently approved treatments, which is intended for the treatment of men with prostate cancer, and TRC694 (formerly JNJ-6420694), a novel, potent, orally bioavailable inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma.